Capodanno, Davide
Mehran, Roxana
Valgimigli, Marco
Baber, Usman
Windecker, Stephan
Vranckx, Pascal
Dangas, George
Rollini, Fabiana
Kimura, Takeshi
Collet, Jean-Philippe
Gibson, C. Michael
Steg, Philippe Gabriel
Lopes, Renato D.
Gwon, Hyeon-Cheol
Storey, Robert F.
Franchi, Francesco
Bhatt, Deepak L.
Serruys, Patrick W.
Angiolillo, Dominick J.
Article History
First Online: 4 July 2018
Competing interests
: D.J.A. declares that he has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Janssen, Merck, PLx Pharma, Pfizer, Sanofi, and The Medicines Company and has received payments for participation in review activities from CeloNova and St Jude Medical. D.J.A. also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions. D.L.B. declares that he has received research funding from Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, and The Medicines Company. He also declares that he is an advisory board member for Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences and was on the Board of Directors of the Boston VA Research Institute and the Society of Cardiovascular Patient Care; he was Chair of the American Heart Association Quality Oversight Committee and is on the Data Monitoring Committees of the Cleveland Clinic, Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, and Population Health Research Institute; he was a Trustee of the American College of Cardiology (ACC), from whom he receives honoraria for his roles as Senior Associate Editor (Clinical Trials and News) at ACC.org and Vice Chair of the ACC Accreditation Committee. He is a member of the clinical trial steering committees of Duke Clinical Research Institute Population Health Research Institute and Harvard Clinical Research Institute. He was Secretary and Treasurer of the Society of Cardiovascular Patient Care, a member of the Continuing Medical Education steering committee for WebMD, and Chair of the National Cardiovascular Data Registry ACTION Registry Steering Committee and of the VA Clinical Assessment, Reporting, and Tracking Research and Publications Committee. He also acts as site co-investigator for Biotronik, Boston Scientific, and St Jude Medical (now Abbott) and conducts unfunded research for FlowCo, Merck, PLx Pharma, and Takeda. Finally, he is Editor in Chief of the Harvard Heart Letter and the Journal of Invasive Cardiology, a guest editor and associate editor of the Journal of the American College of Cardiology, Chief Medical Editor of Cardiology Today’s Intervention, and Deputy Editor of Clinical Cardiology; he receives royalties from Elsevier for his role as Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease. D.C. declares that he has received speaker’s fees or consulting honoraria from AstraZeneca, Bayer, and Sanofi. J.-P.C. declares that he has received research grants from Bristol-Myers Squibb, Boston Scientific, Federation Française de Cardiologie, Medtronic, and Société Française de Cardiologie; consulting fees from Bristol-Myers Squibb and Sanofi Aventis; and lecture fees from AstraZeneca, Bayer Health Care, Bristol-Myers Squibb, and Daiichi-Sankyo. G.D. declares that he has received honoraria from Bayer. C.M.G. declares that he has received honoraria from Bayer, Janssen Pharmaceuticals, Johnson and Johnson, and Portola Pharmaceuticals. H.-C.G. declares that he has received consulting fees from Medtronic and research grants from Abbott Vascular, Biotronik, Boston Scientific, and Medtronic. T.K. declares that he has received honoraria from Sanofi and research grants from Abbott Vascular. R.D.L. declares that he has received research support from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, and Pfizer and consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, and Portola. R.M. declares that she has received consulting fees from Abbott Vascular, Abiomed, Boston Scientific, Bristol-Myers Squibb, Cardiovascular Systems, Elixir, Medscape, Shanghai Bracco Sine Pharmaceutical, and The Medicines Company and executive committee fees from Janssen Pharmaceuticals and Osprey Medical. She also declares that her institution receives funding from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, CardioKinetix, Claret Medical, CSL Behring, Eli Lilly/DSI, Medtronic, Novartis Pharmaceuticals, OrbusNeich, Spectranetics, and Watermark Research Partners. P.W.S. declares that he has received consulting fees and honoraria from Abbott Vascular, Biosensors, Medtronic, Micell Technologies, QualiMed, Sinomed, St Jude Medical, Stentys, Svelte, Philips/Volcano, and Xeltis. P.G.S. declares that he has received research grants from Bayer, Merck, Sanofi, and Servier and has received speaker’s fees or consulting fees from Amarin, Amgen, AstraZeneca, Bayer/Janssen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, and Servier. R.F.S. declares that he has received consultancy fees from Actelion, Avacta, AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, Idorsia, Novartis, PlaqueTec, and The Medicines Company; research grants from AstraZeneca and PlaqueTec; and honoraria from AstraZeneca and Bayer. M.V. declares that he has received research grants from AstraZeneca and Terumo and has received honoraria from Abbott Vascular, Amgen, AstraZeneca, Bayer, Biosensors, Cardinal Health, Daiichi-Sankyo, and Terumo. P.V. declares that he has received speaker’s fees or consulting fees from AstraZeneca, Bayer Health Care, and Daiichi-Sankyo. S.W. declares that he has received institutional research funding from Abbott, Amgen, Boston Scientific, Biotronik, and St Jude Medical. U.B., F.F., and F.R. declare no competing interests.